Placebo multiple doses

DRUG5 trials

Conditions

HealthyIgA Nephropathy

Phase 1

First-in-Human Single and Multiple Dose of GLPG1837

CompletedNCT02325037

Galapagos NVHealthy

Start: 2014-12-31End: 2015-09-30Updated: 2015-09-09

First-in-Human Single and Multiple Dose of GLPG1972

CompletedNCT02612246

Galapagos NVHealthy

Start: 2015-11-30End: 2016-07-31Updated: 2016-07-29

First-in-Human Single and Multiple Dose of GLPG2222

CompletedNCT02662452

Galapagos NVHealthy

Start: 2016-01-31End: 2016-05-31Updated: 2016-07-29

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

CompletedNCT02690961

Tianjin Chasesun Pharmaceutical Co., LTDHealthy

Start: 2016-03-31End: 2016-06-14Updated: 2017-05-03

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

CompletedNCT03945318

Novartis PharmaceuticalsIgA Nephropathy

Start: 2019-04-08End: 2026-06-10Updated: 2026-06-16

Nephrology Dialysis Transplantation2025-10-01

#2889 Changes in proteinuria and kidney function in subgroups of patients with IgAN defined by baseline Gd-IgA1 levels in a Phase 1/2 study of zigakibart

Nephrology Dialysis Transplantation2025-10-01

Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy

Kidney International2025-06-0510 citations

#4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY

Nephrology Dialysis Transplantation2023-06-012 citations

Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study

Advances in Therapy2023-05-262 citations

MO212: Updated Interim Results of A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients With IGA Nephropathy

Nephrology Dialysis Transplantation2022-05-018 citations

MO207: A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IGA Nephropathy

Nephrology Dialysis Transplantation2022-05-011 citations

Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip

Clinical Pharmacology in Drug Development2021-12-0222 citations

FC 040INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY

Nephrology Dialysis Transplantation2021-05-0114 citations

MO286DESIGN OF A PH1, MULTICENTER TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PK/PD OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGAN AND A MULTICENTER, OPEN-LABEL EXTENSION STUDY FOR IGAN PATIENTS WHO PARTICIPATED IN A PRIOR TRIAL OF BION-1301

Nephrology Dialysis Transplantation2021-05-01

P0500RESULTS OF A PHASE 1 TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BION-1301 IN HEALTHY VOLUNTEERS

Nephrology Dialysis Transplantation2020-06-011 citations

Placebo multiple doses

Sponsors

Conditions

Phase 1

Related Papers